

# **CERTIFICATE OF ANALYSIS**

## **HUMAN CELL LINE PROTEIN**

## Human CA19-9

Code No. P291-4

Grade Low Cross Contamination

Lot No.

# **RECEIVER INFORMATION**

**Expiry Date** 

**Manufacture Date** 

**Storage Temperature** Store below -15°C.

**Storage Notes** Avoid freeze thaw cycles. **Shipping Notes** Dry Ice recommended.

#### PRODUCT INFORMATION

**Source** Human carcinoma cell line.

Presentation Single homogenous batch, 0.2µm filtered, supplied frozen in a

0.05M phosphate buffer, pH 7.5 containing 1.0M NaCl, 5mM EDTA

and 0.09% NaN<sub>3</sub>.

**Recovery** In order to meet our customer needs, it should be noted that there

is normally a dispensing overage allowance and the product

recovery may, therefore, be greater than expected.

### **HEALTH AND SAFETY**

**Application** For Research and Manufacturing Only.

#### **Infectious Disease Tests**

Starting material tested using FDA approved tests for:	Result
HIV 1 & 2 antibodies	
Hepatitis B Surface Antigen	
Hepatitis C virus antibodies	
HIV 1 / HBV / HCV (NAT)	
Syphilis	

**Precaution** No test can guarantee the absence of an infectious agent. Please

handle as potentially hazardous.

Material Safety For further information and technical details, please download a

Safety Data Sheet at www.bbisolutions.com or contact your BBI

Account Manager.



# **ANALYSIS**

TESTS	SPECIFICATIONS	RESULTS		
Determination Method				
CA19-9 concentration by Roche Modular	> 100 Ku/ml	Ku/ml		
CA19-9 concentration by Beckman Access (Post QC result to be deleted)	Report result	Ku/ml		
CA125 concentration by Roche Modular.	< 10% of CA19-9	%		
CA15-3 concentration by Roche Modular.	< 10% of CA19-9	%		
CA72-4 concentration by Roche Modular.	< 8% of CA19-9	%		
CEA concentration by Roche Modular.	< 8%* of CA19-9	%		
Protein concentration as determined by Pierce BCA method.	Report result	mg/ml		
Bioburden.	< 100 CFU/ml	Pass/Fail		
* % calculated using conversion 1Ku=1µg.				
Physical appearance Clear colourless frozen liquid.				

**Purity** Total measured contaminants are < 40% of the CA19-9 concentration.

Name:	Position:	
Signed:	Date:	